One of the novel insights presented in this work is the therapeutic potential of MDM2 inhibitors, particularly Idasanutlin, in restoring MHC-I expression and enhancing immune surveillance in TP53 wild-type AML. This evidence concerns the gene TP53 and acute myeloid leukemia.